A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects

Trial Profile

A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2014

At a glance

  • Drugs Lenalidomide (Primary) ; Diphenhydramine; Quinidine; Temsirolimus
  • Indications Acute myeloid leukaemia; Allergic rhinitis; Amyotrophic lateral sclerosis; Breast cancer; Chronic lymphocytic leukaemia; CNS cancer; Colorectal cancer; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Eye neoplasms; Follicular lymphoma; Glioblastoma; Head and neck cancer; Heart failure; Hodgkin's disease; Inflammation; Liver cancer; Malignant melanoma; Mantle-cell lymphoma; Multiple myeloma; Multiple sclerosis; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer; Renal cancer; Rheumatoid arthritis; Soft tissue sarcoma; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top